Neurotechnology Startups funded by Y Combinator (YC) 2026

November 2026

Browse 18 of the top Neurotechnology startups funded by Y Combinator.

We also have a Startup Directory where you can search through over 5,000 companies.

  • Axonnic
    Axonnic
    Y Combinator LogoF2026
    Active • 2 employees • San Francisco
    Axonnic is building the missing data layer for dexterous robotics. Our wearable EMG technology captures human intent, effort and force directly from muscle activity as people demonstrate physical tasks. By revealing the physical signals that video cannot capture, Axonnic gives AI models the data they need to learn more precise and dexterous behaviour. Beyond robotics, this creates a foundation for new forms of human–computer interaction in which technology can understand and respond directly to human movement and intent.
    neurotechnology
    robotics
    data-labeling
  • Preload
    Preload
    Y Combinator LogoF2026
    Active • 3 employees • San Francisco
    Designing and iterating a multimodal hardware stack (currently ego + tactile gloves + EMG) to collect rich and scalable datasets for physical AI. Also interested in how we can use this technology to advance surgery. Built by PhD founders (Johns Hopkins, Caltech) with world-class expertise in brain-computer interfaces (Neuralink, Meta, Paradromics)
    neurotechnology
    robotics
    robotic-surgery
    b2b
    ai
  • Dydema
    Dydema
    Y Combinator LogoF2026
    Active • 2 employees • San Francisco
    We’re building a brain-computer interface anyone can wear, so you can use a computer at the speed of thought. To get there, we’re recording brain data at model company scale.
    hardware
    neurotechnology
    neuroinformatics
    consumer
    ai
  • Parasma
    Parasma
    Y Combinator LogoS2026
    Active • 2 employees • San Francisco
    We train human brain cells for compute
    machine-learning
    neurotechnology
    ai
  • Exin Therapeutics
    Exin Therapeutics
    Y Combinator LogoW2025
    Active • 9 employees • San Francisco
    We are developing therapies for disorders driven by dysfunctional neural circuits. To develop these therapies, we are building an agentic discovery platform that learns from experiments in our own in vivo lab. Our agents use CircuitATLAS to connect disease phenotypes with the neural circuits, cell types and molecular mechanisms, identify therapeutic targets and design experiments to test them. Our cross-species models learn from large-scale neural activity data to identify conserved circuit states and help predict how an intervention’s effects may translate from preclinical models to humans. At our Data Foundry in Manila, our team of RAs test these hypotheses in vitro and in vivo. The results refine our models and guide the next set of experiments. This lab-in-the-loop approach allows our agents to develop and test ideas against experimental evidence throughout discovery. We are starting with epilepsy, with the goal of developing first-in-class therapies across a full spectrum of disorders driven by dysfunctional brain activity. Publications: - CircuitATLAS (https://arxiv.org/abs/2610.09643). Target discovery platform which combines mechanistic reasoning with an in vivo lab-in-the-loop. AI agents identify therapeutic targets and design experiments that our research teams execute in the lab. The resulting biological data feeds back into the discovery process to iteratively refine hypotheses and validate new interventions. - Cross species representation learning (https://arxiv.org/abs/2610.11222). Aligning mouse and human neural activity to predict clinical drug efficacy from preclinical data.
    ai-powered-drug-discovery
    neurotechnology
  • Auricle
    Auricle
    Y Combinator LogoW2021
    Active • 2 employees • San Francisco
    Auricle is a medical device company building a breakthrough neurostimulation implant to restore hearing in millions of patients who no longer benefit from hearing aids, get less than 60% on a word recognition test, but aren't prepared to make the jump to a cochlear implant. Our approach preserves remaining natural hearing through a reversible and less invasive surgery, addressing the key concerns that hold most patients back from getting a cochlear implant (currently the only treatment option for these patients). The company spun out of Stanford Biodesign having completed two acute human clinical studies demonstrating the approach will work. The team is now focused on developing their full implant system for their first clinical trial. Auricle addresses a currently unserved profile of hearing loss that affects a growing population of 3.5 million patients in the US and represents an immediately accessible $1.2B market opportunity with existing reimbursement.
    hard-tech
    neurotechnology
    health-tech
    healthcare
    medical-devices
  • Craniometrix
    Craniometrix
    Y Combinator LogoW2022
    Active • 64 employees • New York City
    Dementia is tough – but it can be easier. Turns out, if you give families the right non-clinical coaching and support, you can avoid 30% of hospitalizations for these patients. And Medicare has recently started paying for that coaching. We leverage AI to provide best-in-class care, alleviating the burden on providers. Come help us build!
    neurotechnology
    health-tech
    digital-health
  • Torpedo Therapeutics
    Torpedo Therapeutics
    Y Combinator LogoW2022
    Active • 5 employees • Boston
    We are building high-precision implantable neuromodulation devices that can sense and stimulate neural activity in the brain with the goal of transforming the efficacy and adoption of deep brain stimulation (DBS), an existing FDA-approved therapy used to treat Parkinson’s, essential tremor and epilepsy.
    neurotechnology
    biotech
    medical-devices
  • Actipulse Neuroscience
    Actipulse Neuroscience
    Y Combinator LogoW2022
    Active • 38 employees • Mexico City, Mexico
    Non-invasive brain stimulation is a widely-utilized, FDA cleared treatment used for patients diagnosed with depression, but is limited to a hospital setting due to the cost of the device, and complexity of treatment application. Our proprietary brain stimulation device allows patients to be treated directly from their home, with the same efficacy, and at a lower cost of treatment. Currently in FDA pivotal phase for Major Depressive Disorder, and Pilot phase for Alzheimer's and Parkinson diseases.
    mental-health-tech
    neurotechnology
    medical-devices
  • Mindstate Design Labs
    Mindstate Design Labs
    Y Combinator LogoS2021
    Active • 7 employees • San Francisco
    Mindstate Design Labs is building the closed-loop science & engineering stack for rational psychoactive effect design. Our molecular-experience interface links molecular biology to the human psychopharmacodynamic profile to convert informal constructs like clarity, presence, or motivation into high-dimensional design targets. Our clinical program is a sequence of human demonstrations that psychoactive effects can be decomposed, recombined, and synthesized. The first controlled study decomposed hallucinations from the broader hallucinogen profile; the next is designed to selectively upregulate aesthetic salience to treat anhedonia in major depressive disorder. We’re progressively digitizing the molecular interface through which biology shapes what intelligence wants.
    hard-tech
    neurotechnology
    biotech
    ai
  • Well Principled
    Well Principled
    Y Combinator LogoS2019
    Active • 3 employees • St. Louis, MO, USA
    We aren’t building AI to replace "knowledge work” that requires neither, but to bolster the working human intellect which has never failed to discover new paths to prosperity. For all their success, mainstream approaches to AI have fundamental limitations preventing them from solving critical classes of problems. We are building a new AI architecture from first principles to break from these limitations. The status quo has ossified around the supervised, brute-force pretraining paradigm. These systems do not, and cannot, handle the essential skills of continual learning, goal discovery, novel planning, and the creation of new knowledge. These limitations are not trivial. Our national prosperity depends directly on overcoming these limitations, because the essential skills underlie the skilled trades. From electricians to machinists to nurses, apprentice tradespeople in all of these fields learn “skilled improvisation” where every solution is novel, and even the goal must be discovered. Prosperity demands the precise capabilities where status quo AI is structurally weak. Worse, these limitations will not be overcome with more compute or training data. They are inescapable consequences of the underlying technologies of supervised learning, neural networks, transformers, backprop, and gradient descent. Progress requires independence from them. We are building a new AI architecture by reverse-engineering the system that got us this far: the human brain. By triangulating between neuroscience, cognitive science, and the evolutionary elaboration of brains, we have identified the brain’s algorithms to (a) continually learn a causal world model (b) select goals to both achieve and learn to achieve more (c) plan to reach novel goals, and (d) creatively produce new knowledge. Join us in building intelligence with ingenuity to bolster the skilled trades.
    hard-tech
    neurotechnology
    robotics
    ai
  • BrainKey
    BrainKey
    Y Combinator LogoW2019
    Active • 20 employees • San Francisco
    BrainKey is an AI-driven digital healthcare company with a mission to create a world free from dementia.
    neurotechnology
    health-tech
    digital-health
    ai
  • Nectome
    Nectome
    Y Combinator LogoW2018
    Active • 9 employees • Portland, OR, USA
    Nectome has created a new method for whole-body, whole-brain, human end-of-life preservation for the purpose of future revival. Our protocol is capable of preserving every synapse and every cell in the body with enough detail that current neuroscience says long-term memories are preserved. It's compatible with traditional funerals at room temperature and stable for hundreds of years at cold temperatures.
    neurotechnology
    biotech
    healthcare
  • BIOS Health
    BIOS Health
    Y Combinator LogoW2017
    Active • 45 employees • Boston
    BIOS Health was previously called Cambridge Bio-Augmentation Systems (CBAS) and focused on prosthetic neural interfaces as a first market. Now we use
    neurotechnology
    ai
  • Voyage Biomedical
    Voyage Biomedical
    Y Combinator LogoS2019
    Acquired • 3 employees • San Francisco
    Acquired by Penumbra (NYSE:PEN).
    hardware
    neurotechnology
    medical-devices
  • Rain Neuromorphics
    Rain Neuromorphics
    Y Combinator LogoS2018
    Acquired • 12 employees • San Francisco
    At Rain Neuromorphics, we envision a future where every device possesses a dynamic and continuously learning AI brain. Neural Networks are the most powerful engines behind today's AI, but simulations require massive amounts of power and time to learn all of the synaptic connections. As opposed to a simulation, our neuromorphic hardware is a physical artificial neural network, composed of spiking neurons and physical synapses. We combine unique electroceramic materials, nanofabrication techniques, and biologically plausible models of learning to create the Memristive Nanowire Neural Network (MN3), a new type of AI chip. The MN3 can possess over ten million spiking neurons per square centimeter, and uses far less power than conventional GPUs and CPUs.
    hardware
    neurotechnology
    ai